The industry-academic partnership is expected to boost clinical trials on investigational drugs and outcomes research, in gynecological cancers.
The University of Texas MD Anderson Cancer Center
has established a strategic partnership with AstraZeneca focused on ovarian and other gynecologic cancers. MD Anderson and AstraZeneca are going to conduct multiple, parallel clinical and clinically related studies with the goal of improving treatment results in oncology patients.
The collaboration is an unparalleled approach, as the two partners will be dedicated to both clinical trials on investigational treatments, and epidemiological and outcome studies. In addition to enhancing therapeutic outcomes, AstraZeneca and MD Anderson believe they can alter the way in which the industry and the academia approach research and collaborative work, as they want to deepen partnerships and accelerate the development of treatments for women with high unmet medical needs.
Link to the press release by MD ANderson: http://bit.ly/1zk7twz
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More